330 related articles for article (PubMed ID: 9822092)
1. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
[TBL] [Abstract][Full Text] [Related]
2. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
[TBL] [Abstract][Full Text] [Related]
3. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
[TBL] [Abstract][Full Text] [Related]
5. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
[TBL] [Abstract][Full Text] [Related]
6. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
de Faire U; Ericsson CG; Hamsten A; Nilsson J
Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
[TBL] [Abstract][Full Text] [Related]
7. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).
Vakkilainen J; Steiner G; Ansquer JC; Aubin F; Rattier S; Foucher C; Hamsten A; Taskinen MR;
Circulation; 2003 Apr; 107(13):1733-7. PubMed ID: 12665498
[TBL] [Abstract][Full Text] [Related]
8. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
Ericsson CG
Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
[TBL] [Abstract][Full Text] [Related]
9. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol.
Syvänne M; Nieminen MS; Frick MH; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Ehnholm C; Taskinen MR
Circulation; 1998 Nov; 98(19):1993-9. PubMed ID: 9808595
[TBL] [Abstract][Full Text] [Related]
10. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
[TBL] [Abstract][Full Text] [Related]
11. Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).
Ericsson CG; Nilsson J; Grip L; Svane B; Hamsten A
Am J Cardiol; 1997 Nov; 80(9):1125-9. PubMed ID: 9359536
[TBL] [Abstract][Full Text] [Related]
12. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction.
Tornvall P; Karpe F; Carlson LA; Hamsten A
Atherosclerosis; 1991 Sep; 90(1):67-80. PubMed ID: 1799399
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression.
Mack WJ; Krauss RM; Hodis HN
Arterioscler Thromb Vasc Biol; 1996 May; 16(5):697-704. PubMed ID: 8963728
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of bezafibrate on improvement of atherogenic lipoproteins in Japanese familial combined hyperlipidemic patients with or without impaired glucose tolerance.
Hayashi K; Kurushima H; Kuga Y; Shingu T; Tanaka K; Yasunobu Y; Nomura K; Ohtani H; Hiraga T; Toyota Y; Katano T; Sakai-Ohta K; Kajiyama G
Cardiovasc Drugs Ther; 1998 Mar; 12(1):3-12. PubMed ID: 9607127
[TBL] [Abstract][Full Text] [Related]
15. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.
Rosenson RS; Otvos JD; Freedman DS
Am J Cardiol; 2002 Jul; 90(2):89-94. PubMed ID: 12106834
[TBL] [Abstract][Full Text] [Related]
16. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
[TBL] [Abstract][Full Text] [Related]
17. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Goa KL; Barradell LB; Plosker GL
Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
[TBL] [Abstract][Full Text] [Related]
18. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction.
Hamsten A; Walldius G; Szamosi A; Dahlen G; de Faire U
Circulation; 1986 Jun; 73(6):1097-110. PubMed ID: 3698244
[TBL] [Abstract][Full Text] [Related]
19. Change in very low-, low-, and high-density lipoproteins during lipid lowering (bezafibrate) therapy: studies in type IIA and type IIb hyperlipoproteinaemia.
Gavish D; Oschry Y; Fainaru M; Eisenberg S
Eur J Clin Invest; 1986 Feb; 16(1):61-8. PubMed ID: 3084275
[TBL] [Abstract][Full Text] [Related]
20. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
Saku K; Sasaki J; Arakawa K
Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
